There were 762 press releases posted in the last 24 hours and 171,407 in the last 365 days.

Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 1, 2017

BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, March 1, 2017 at 8:00 a.m. ET to discuss its fourth quarter and full year 2016 financial results and provide corporate updates.

/EIN News/ -- To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 74238520. The call will be webcast live with slides and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.

Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.

Keryx Biopharmaceuticals Contact:

Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
lora.pike@keryx.com

Primary Logo